720 related articles for article (PubMed ID: 33801133)
1. The Gut-Liver Axis in Cholestatic Liver Diseases.
Blesl A; Stadlbauer V
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801133
[TBL] [Abstract][Full Text] [Related]
2. The gut microbial influence on cholestatic liver disease.
Kummen M; Hov JR
Liver Int; 2019 Jul; 39(7):1186-1196. PubMed ID: 31125502
[TBL] [Abstract][Full Text] [Related]
3. Secondary Sclerosing Cholangitis in Critically Ill Patients Alters the Gut-Liver Axis: A Case Control Study.
Blesl A; Jüngst C; Lammert F; Fauler G; Rainer F; Leber B; Feldbacher N; Stromberger S; Wildburger R; Spindelböck W; Fickert P; Horvath A; Stadlbauer V
Nutrients; 2020 Sep; 12(9):. PubMed ID: 32906634
[TBL] [Abstract][Full Text] [Related]
4. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
6. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
7. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
8. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Shah A; Macdonald GA; Morrison M; Holtmann G
Am J Gastroenterol; 2020 Jun; 115(6):814-822. PubMed ID: 32250997
[TBL] [Abstract][Full Text] [Related]
10. Microbial Players in Primary Sclerosing Cholangitis: Current Evidence and Concepts.
Özdirik B; Schnabl B
Cell Mol Gastroenterol Hepatol; 2024; 17(3):423-438. PubMed ID: 38109970
[TBL] [Abstract][Full Text] [Related]
11. Gut-Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology.
Maroni L; Ninfole E; Pinto C; Benedetti A; Marzioni M
Cells; 2020 Mar; 9(3):. PubMed ID: 32192118
[TBL] [Abstract][Full Text] [Related]
12. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
Guo Z; He K; Pang K; Yang D; Lyu C; Xu H; Wu D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673905
[TBL] [Abstract][Full Text] [Related]
13. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
[TBL] [Abstract][Full Text] [Related]
14. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
15. Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.
Liu Q; Li B; Li Y; Wei Y; Huang B; Liang J; You Z; Li Y; Qian Q; Wang R; Zhang J; Chen R; Lyu Z; Chen Y; Shi M; Xiao X; Wang Q; Miao Q; Fang JY; Gershwin ME; Lian M; Ma X; Tang R
Gut; 2022 May; 71(5):899-909. PubMed ID: 34035120
[TBL] [Abstract][Full Text] [Related]
16. Novel and emerging therapies for cholestatic liver diseases.
Goldstein J; Levy C
Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
[TBL] [Abstract][Full Text] [Related]
17. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
18. [Gut-liver axis: How intestinal bacteria affect the liver].
Konturek PC; Harsch IA; Konturek K; Schink M; Zopf Y
MMW Fortschr Med; 2018 Nov; 160(Suppl 5):11-15. PubMed ID: 30367438
[TBL] [Abstract][Full Text] [Related]
19. Immunopathogenesis of Primary Biliary Cholangitis, Primary Sclerosing Cholangitis and Autoimmune Hepatitis: Themes and Concepts.
Trivedi PJ; Hirschfield GM; Adams DH; Vierling JM
Gastroenterology; 2024 Jun; 166(6):995-1019. PubMed ID: 38342195
[TBL] [Abstract][Full Text] [Related]
20. Multiple therapeutic targets in rare cholestatic liver diseases: Time to redefine treatment strategies.
Gerussi A; D'Amato D; Cristoferi L; O'Donnell SE; Carbone M; Invernizzi P
Ann Hepatol; 2020; 19(1):5-16. PubMed ID: 31771820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
